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Abstract
Background: Podoplanin is a membrane mucin that, among a series of tissues, is expressed on late osteoblasts
and osteocytes. Since recent findings have focussed on podoplanin's potential role as a tumour progression factor,
we aimed at identifying regulatory elements conferring PDPN promoter activity. Here, we characterized the
molecular mechanism controlling basal PDPN transcription in human osteoblast-like MG63 versus Saos-2 cells.
Results: We cloned and sequenced 2056 nucleotides from the 5'-flanking region of the PDPN gene and a
computational search revealed that the TATA and CAAT box-lacking promoter possesses features of a growth-
related gene, such as a GC-rich 5' region and the presence of multiple putative Sp1, AP-4 and NF-1 sites. Reporter
gene assays demonstrated a functional promoter in MG63 cells exhibiting 30-fold more activity than in Saos-2
cells. In vitro DNase I footprinting revealed eight protected regions flanked by DNaseI hypersensitive sites within
the region bp -728 to -39 present in MG63, but not in Saos-2 cells. Among these regions, mutation and supershift
electrophoretic mobility shift assays (EMSA) identified four Sp1/Sp3 binding sites and two binding sites for yet
unknown transcription factors. Deletion studies demonstrated the functional importance of two Sp1/Sp3 sites for
PDPN promoter activity. Overexpression of Sp1 and Sp3 independently increased the stimulatory effect of the
promoter and podoplanin mRNA levels in MG63 and Saos-2 cells. In SL2 cells, Sp3 functioned as a repressor,
while Sp1 and Sp3 acted positively synergistic. Weak PDPN promoter activity of Saos-2 cells correlated with low
Sp1/Sp3 nuclear levels, which was confirmed by Sp1/Sp3 chromatin immunoprecipitations in vivo. Moreover,
methylation-sensitive Southern blot analyses and bisulfite sequencing detected strong methylation of CpG sites
upstream of bp -464 in MG63 cells, but hypomethylation of these sites in Saos-2 cells. Concomitantly, treatment
with the DNA methyltransferase inhibitor 5-azaCdR in combination with trichostatin A (TSA) downregulated
podoplanin mRNA levels in MG63 cells, and region-specific in vitro methylation of the distal promoter suggested
that DNA methylation rather enhanced than hindered PDPN transcription in both cell types.
Conclusion: These data establish that in human osteoblast-like MG63 cells, Sp1 and Sp3 stimulate basal PDPN
transcription in a concerted, yet independent manner, whereas Saos-2 cells lack sufficient nuclear Sp protein
amounts for transcriptional activation. Moreover, a highly methylated chromatin conformation of the distal
promoter region confers cell-type specific podoplanin upregulation versus Saos-2 cells.
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Background
Podoplanin represents a type I integral membrane protein
of the mucin-type family. Its 162 aa protein core is exten-
sively O-glycosylated, which results in a doubling of the
molecular weight up to 45 kDa. The podoplanin mRNA
was identified for the first time in the murine osteoblastic
cell line MC3T3-E1 [1], and later it was found to be
expressed in murine colon carcinoma and melanoma cells
[2], in the stromal cells of peripheral lymphoid tissue [3],
in skeletal muscle, heart, placenta, lung, skin, bone and
brain [4,5]. Podoplanin has also been detected in the cili-
ary epithelium of the eye [6], in transformed epidermal
keratinocytes and fibroblasts [7] and in the choroid plexus
and neuronal cells of the CNS [8]. In our lab, podoplanin
has been discovered as a membrane protein of glomerular
epithelial cells, which was found to be downregulated in
puromycin nephrosis and caused a flattening of podo-
cytes, hence its designation "podoplanin" [9]. Moreover,
podoplanin has been found in endothelia of lymphatic
vessels [4] and has been established as a discrimination
marker between lymphatic (LEC's) and blood endothelial
cells (BEC's) [10]. The widespread localization of podo-
planin has lead to a multiplicity of synonyms for its
expression forms of human, murine and rat origin:
murine OTS-8 [1], gp38 [3], T1α [11], PA2.26 antigen [7],
RANDAM-2 [8] or Aggrus [12], rat E11 antigen [4] or
RTI40 [13], and human gp36 [5].
The exact biological function of podoplanin remains con-
troversial and seems to be versatile. Though its highly
abundant expression in a multiplicity of tissues, distinct
cell-specificities and functions have been described. In the
lung, podoplanin has been shown to be restricted to type
I lung alveolar cells [11], where it also functions as the
main receptor for influenza C virus [14]. Also quite early,
podoplanin has been described as a platelet aggregating
factor in murine and human colon carcinoma [15] and
murine melanoma [2]. Podoplanin/T1α deficiency in
mice lead to disruption of normal lymphatic vasculature
formation and development of lymphedema [16]. More-
over, podoplanin has been demonstrated to bind chem-
okines in the lymphatic vessels of renal transplants [17]
and to promote cell motility by downregulating E-cad-
herin expression in oral squamous cell carcinomas [18].
Recent studies, therefore, have focussed on its potential
role as a key player in tumour vessel formation [19] and
as a tumour progression factor in skin [20] and germ line
carcinomas [21]. Podoplanin becomes upregulated in
cells of the invasive cancer front, where it induces filopo-
dia formation and promotes tumour cell migration [22].
Rat podoplanin/E11 has been reported to be a marker for
late steps in the differentiation pathway of the osteoblas-
tic lineage, being expressed by mature osteoblasts and
newly formed osteocytes [4]. The human osteosarcoma
cell lines MG63 and Saos-2 used in this study represent
differentiated late stage osteoblasts, nonetheless showing
different degrees of maturation. Whereas MG63 cells
exhibit a premature fibroblast-like state, Saos-2 cells dis-
play an epithelial phenotype and appear more rounded
[23]. Podoplanin/E11 was detected in a restricted subset
of osteoblastic cells which is in direct contact with bone
matrix, suggesting a functional role as an anti-adherent
molecule according to its high sialic acid content. Never-
theless, the function of podoplanin in the bone is
unknown.
Despite considerable progress that has been made in
describing the expression pattern of podoplanin under
normal and various pathological conditions, little is
known about the mechanisms leading to the widespread
gene activity of podoplanin. Due to its certain specificities
and potential role in tumour progression, the regulation
of PDPN gene expression is of high interest. In an early
study, podoplanin/OTS-8 could be induced by phorbo-
lester in the mouse osteoblastic cells MC3T3-E1 [1], and
therefore it was defined as a target gene for early response
proteins. However, the molecular mechanism underlying
podoplanin expression in osteoblasts remains largely
unclear. In rat alveolar type I cells, Sp1 elements and a thy-
roid transcription (TGT3/HNF-3) factor site have been
identified as essential for transcriptional activation of
podoplanin/T1α [24,25]. In lymphatic endothelial cells,
podoplanin/T1α is an early responder to the lymphatic-
specific master regulator Prox-1 [26], and recently, podo-
planin expression was shown to be under control of
endogenously produced IL-3 in human lymphatic
endothelial precursor cells [27]. However, no direct cis-
and trans-acting regulatory elements involved in cell-spe-
cific upregulation of human podoplanin have been eluci-
dated so far.
In this study, we demonstrate a cell-specific difference
between MG63 and Saos-2 cells in the binding of nuclear
proteins to sequences immediately adjacent and more dis-
tal to the transcription start site of the PDPN promoter.
We identify four Sp1/Sp3 binding-sites inside a 654 bp
element upstream of the PDPN gene and establish that
two of them mediate basal transcription in MG63 cells,
whereas Saos-2 cells seem to lack sufficient amounts of
nuclear Sp1/Sp3 for PDPN promoter activation. We show
that these two functional Sp-binding sites may involve
further activator elements. Moreover, we assess the func-
tional hierarchy of another regulatory system, the chro-
matin modification, which is strongly altered in MG63
versus Saos-2 cells distal of the core promoter and leads to
enhanced expression of podoplanin.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Results
Podoplanin mRNA expression in the human osteoblastic 
cell lines MG63 and Saos-2
To identify cell lines which are positive for podoplanin
expression, reverse transcription PCRs were performed
with a series of human cell lines of different origin (Fig.
1A). The osteoblastic osteosarcoma cell line MG63 exhib-
ited a strong RT-PCR signal, whereas Saos-2 osteosarcoma
cells lacked it. This result was confirmed by real-time PCR
analyses showing that MG63 cells contained three logs
more podoplanin mRNA transcripts than Saos-2 cells.
While in MG63 cells the podoplanin mRNA population
represented approximately 3% of GAPDH mRNA popula-
tion, it made up just 0.003% in Saos-2 cells (Fig. 1B). A
Northern blot analysis revealed the presence of two podo-
planin transcript variants in MG63 cells (Fig. 1C). A 2.8 kb
transcript corresponding to the full length mRNA was
seen, and a shorter species was detected at 1.1 kb. As deter-
mined by 3' RACE analysis using MG63-derived cDNA,
this short mRNA species represented a transcriptional var-
iant ending after a cryptic polyA-signal at bp 345 of the
2068 bp 3'-UTR (data not shown).
Reverse transcription PCR applying a series of nine
ascending 5' primers suggested that in MG63 cells, podo-
planin mRNA was initiated at multiple sites mostly
located between bp -97 and +1 of the 5'-flanking region
(Fig. 1D). In 5' RACE experiments using MG63-derived
cDNA, the 5'-length of mRNA transcripts and their fre-
quency of occurrence was determined. The positions and
frequencies of cDNA variants derived from 5' RACE anal-
ysis are summarized in Fig. 1E. The major transcription
start site of podoplanin mRNA was allocated to the posi-
tion designated +1 (Fig. 1E and 2A).
Isolation and structural analysis of the human PDPN 
promoter
The human PDPN gene 5' flanking region was isolated by
PCR amplifications from a genomic BAC clone and subse-
quent staggered cloning. When comparing the isolated
promoter sequence with the human chromosome 1
sequence, sequence identity was confirmed despite a sin-
gle base difference at bp -415 (C in BAC clone versus A in
the database). DNA sequence analysis using the Transfac
database showed that the 5' flanking region lacked a con-
sensus TATA box, whereas a GATA box (GATAAA) was
localized 31 nucleotides upstream of the main mRNA
transcription initiation site (Fig. 2A). The PDPN gene 5'-
flanking region was characterized by a high GC content
and revealed the existence of several potential Sp1 tran-
scription factor sites. Moreover, putative binding sites for
the basic transcription factors AP-2, AP-4, C/EBP, and NF-
1, but not for osteoblast-specific factors were detected
along the isolated PDPN promoter sequence (Fig. 2A).
The PDPN promoter is transcriptionally regulated in 
MG63 and Saos-2 cells
Genomic DNA sequencing of the promoter sequence in
Saos-2 cells confirmed that lack of PDPN transcription
was not due to deletion mutations (data not shown).
Thus, MG63 and Saos-2 cells proved to be a suitable cell
system for investigation of transcriptional podoplanin
regulation. To assess which portions of the promoter were
involved in regulation of podoplanin expression, reporter
plasmids harboring progressive deletions from the 5' end
of the bp -1885/+171 PDPN  flanking region were set
according to putative binding sites of transcription factors
(Fig. 2A). The sixteen promoter fragments were inserted
upstream of a luciferase reporter gene (Fig. 2B) and were
evaluated in transient expression analyses. Luciferase tran-
scription was consistently 30 times more active in MG63
than in Saos-2 cells (Fig. 2C). In MG63 cells, bp -1104/
+171 construct provided highest promoter activity (761
Luc/Ren × 100), whereas Saos-2 cells exhibited highest
normalized luciferase activity with bp -498/+171 con-
struct (27 Luc/Ren × 100). Transcriptional activity dimin-
ished progressively with further deletion of the 5' region,
showing three activity minima with the constructs bp -
666/+171, -261/+171 and -76/+171 in MG63 cells, and
with constructs bp -186/+171 and -76/+171 in Saos-2
cells, which indicated the loss of positive regulatory ele-
ments (Fig. 2C). The low promoter activity of the smallest
bp -26/+171 construct in both cell lines suggested that the
171 bp spanning 5'-UTR of podoplanin mRNA was not
involved in upregulation of promoter activity. These data
showed that the 1028 bp 5' region contained motifs pro-
viding basic PDPN  promoter activity, whereas rather
silencing motifs bound to the more upstream bp -1885/-
1104 region.
Nuclear proteins of MG63 and Saos-2 cells bind to the 
PDPN promoter
To more precisely define cis-acting DNA sequences
responsible for cell-type specific PDPN  transcription,
seven overlapping DNA probes encompassing bp -1169 to
+171 of the PDPN promoter (Fig. 3A) were used for in
vitro  DNaseI footprinting assays. With MG63 nuclear
extracts, eight protected regions, fp8 – fp1, were identified
with five probes (Fig. 3B), while probes EB and SB exhib-
ited no differential DNaseI digestion pattern (data not
shown). Complexes fp6, fp5 and fp4 were detected on
both the coding and the noncoding DNA strand (Fig. 3B),
and footprinting region fp1 became also visible with Saos-
2 nuclear extracts (Fig. 3B). Moreover, digestional modi-
fied regions flanking the protected regions emerged along
the probes (Fig. 3, arrowheads), additionally indicating
the presence of DNA-binding proteins.
To determine whether the detected elements indeed
bound nuclear proteins, gel shift assays were performedBMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Podoplanin mRNA transcription and transcriptional initiation in the human osteoblast-like cell line MG63 Figure 1
Podoplanin mRNA transcription and transcriptional initiation in the human osteoblast-like cell line MG63. A) 
PDPN transcription was analyzed using primers specific for podoplanin cDNA (see "Material and Methods"). The human cell 
lines are: MG63 and Saos-2, osteosarcoma cells; HUVEC, umbilical vein endothelial cells; EAhy926, endothelial-like cells; 
Met5A, pleural mesothelial cells; A549, type II alveolar lung carcinoma cells; Raji, Burkitt's B-lymphoma cells; JY, B-lymphoblas-
toid cells; K562, erythroleukemia cells; CCL, "centrocyte-like" B-lymphocytes; HL60, promyeloid cells. B) Real-time PCR anal-
ysis of PDPN transcription in MG63 versus Saos-2 cells. Results ± S.D. of three independent PCRs are shown. Transcript levels 
are relative to GAPDH mRNA content. C) Northern blot analysis of podoplanin mRNA fragments in MG63 versus Saos-2 
cells. D) RT-PCR determination of transcription initiation sites in MG63 cells. The lane numbers correspond to the RT-PCR 5' 
primers in Table 1. They were tested together with 3' primer hPPrev (+114/+96) for their ability to amplify the corresponding 
sequences in cDNA preparations of MG63 cells. PCR products are shown on an agarose gel stained with ethidium bromide. 
Lanes L: DNA ladder, Lane C: Negative control containing no template DNA for PCR reaction. E) Sequencing results of 48 
clones retrieved by 5' RACE from MG63 cells. The 5' cDNA endings and their frequency are indicated above the sequence 
stretch.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Table 1: Primer sequences used in this study.
Name Sequence (5'→3') a Experiment b
hPP rev (+207/+178) CACATCGTTCCCGTTGAGTTGTTGCTCTCC RT-PCR
hPP 1 (+1/+19) AACTGCAAAGTTTGCTGTC RT-PCR
hPP 2 (-16/+3) CGCTCGGAAAGTTCTCAAC RT-PCR
hPP 3 (-35/-17) GAGAGATAAATGCTGACTC RT-PCR
hPP 4 (-52/-33) CTCCCCCGCCTCCTCGGGA RT-PCR
hPP 5 (-68/-50) CTTGCGGCCGACCCCGCTC RT-PCR
hPP 6 (-83/-65) CCGGACGGAGACCACCTTG RT-PCR
hPP 7 (-97/-79) CGGGCCTAGCGCGCCCGGA RT-PCR
hPP 8 (-108/-90) GAGCCCGAGGGCGGGCCTA RT-PCR
hPP 9 (-125/-107) TTGGCGCCGGCCAAACAGA RT-PCR
hPP rev (+114/+96) AGCCTGGAGGAGCGCGAC RT-PCR
FII (-1885/-1866) GCAATGAGCTCATCCACTAACTCCTTCATCC Cloning, LA
F I (-857/-840) GCAATGAGCTCACGTAAGTTCTCTGGTTG Cloning, LA
RII (-783/-803) GCAATCTCGAGAATCCTCACTTTACTGGTTTA Cloning
RI (+154/+171) GCAATCTCGAGCCGAGCAGCAAGATTCTG Cloning, LA
F1 (-1642/-1616) TTGAATAAAGCGGGCCATC LA
F2 (-1378/-1360) TCATCTTCTAGGTTCAGGT LA
F3 (-1104/-1086) ACAATCTCTCCTGTGATTC LA
F4 (-666/-658) ACAGCATCGCAGCGCTGGA LA
F5 (-498/480) ACCAGCGCGGGCCGCCTCT LA
F6 (-361/-343) CACTTCTGCCCATAACAAG LA
F7 (-261/-243) AACCCCGTTTGTTGCATGT LA
F8 (-232/-214) CCTCCTGTTGTTGAGCAGA LA
F9 (-186/-168) AGTCCTGGCGGCCCCCGCA LA
F10 (-159/-141) CCTGTAACTTTAAACCTGG LA
F11 (-114/-96) CAAACAGAGCCCGAGGGCG LA
F12 (-76/-58) GAGACCACCTTGCGGCCGA LA
F13 (-38/-20) CGGGAGAGATAAATGCTGA LA
F14 (-26/-8) ATGCTGACTCCGCTCGGAA LA
fp 1 CCGCTCCCCCGCCTCCTCGGGA EMSA
fp 1 mut CCGCTCCACATAATCCTCGGGA Mutation
fp 2 GAGCCCGAGGGCGGGCCTAGCG EMSA
fp 2 mut GAGCCCGATGATAAGCCTAGCG Mutation
fp 3 GATCATCGTTTTGGCGCCGGCCAA EMSA
fp 4 CAGATGACGGCCAACTTTTTTTGTTTTTAAGCCATCAAA EMSA
fp 5 CCAAACTCCCCCCACCAGCCAG EMSA
fp 5 mut CCAAACTCTACAGACCAGCCAG Mutation
fp 6 TTTTCAAAACTGCCAAAGCC EMSA
fp 7 CACCGCTTGGCCCGGCCTAATCC EMSA
fp 7 mut CACCGCTTGGATCTTGCCTAATCC Mutation
fp 8 GGACACAGGTTTGCGACCAGGACGGT EMSA
Bis-fwd 1 GTTAGGGTTTGTAGTTTTGGTGG BS
Bis-rev 1 CACCACAACCACAAACCCAACCT BS
Bis-fwd 2 GAGGGTGAATTAGGTTTGGAAGGGG BS
Bis-rev 2 CAACCCACACTAATCAATTACACCC BS
Bis-fwd 3 GAGTTGTTGGTTTTATTTGGTTTAGGAGGGTGAG BS
Bis-rev 3 CTATTCTACTTATATATAACTCCAAAATCACACAC BS
a Sequences protected in DNase I footprinting are underlined; mutated nucleotides are indicated in bold italics.
b RT-PCR, reverse transcription PCR; LA, Luciferase assay; EMSA, electrophoretic mobility shift assay; BS, bisulfite sequencing.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Structure and activity of the human PDPN 5'-flanking region in MG-63 and Saos-2 cells Figure 2
Structure and activity of the human PDPN 5'-flanking region in MG-63 and Saos-2 cells. A) Nucleotide sequence 
and putative regulatory elements within bp -857/+205 of the 5'-flanking region of the human PDPN gene. The major transcrip-
tion start site is indicated with an asterisk at +1. Putative regulatory elements highlighted by underlining were identified using 
the Transfac database. Shown are only sites which are conserved between the human, murine and rat promoter. Numbers on 
the left and right refer to the nucleotide position relative to the major transcription start site. The scheme below shows the 
relative positions of these putative transcription factor binding sites within bp -1885/+205. AP, activating enhancer binding pro-
tein; C/EBPβ, CCAAT/enhancer binding protein β; ETF, EGFR-specific transcription factor; ICSBP, interferon consensus 
sequence binding protein; NF-1, nuclear factor 1. B) Schematic representation of stepwise 5' deletions of the PDPN 5' flanking 
region cloned upstream of the luciferase reporter gene into the pGL3 vector. Negative numbers indicate the 5' end of the pro-
moter fragment relative to the major transcription start site at +1. C) Luciferase activity of 5' deletion constructs were 
assessed in MG63 and Saos-2 cells 24 h after transfection with equal stoichiometric plasmid amounts and a constant amount of 
internal control Renilla luciferase plasmid as described under "Methods". Luciferase activity was normalized to Renilla activity 
and is relative to the longest bp -1885/+171 construct, which was set at 100%. The average ± S.D. for three to six independent 
transfection experiments, each performed in triplicates, is shown. Statistical analysis was performed using student's t-test, and 
is as follows: *, p < 0.05, **, p < 0.01, ***, p < 0.001. The statistical analysis indicates a significant promoter activity difference 
between the consecutive deletion-constructs.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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In vitro DNaseI footprint analysis of protein-binding to the PDPN promoter Figure 3
In vitro DNaseI footprint analysis of protein-binding to the PDPN promoter. A) DNA probes used in DNaseI foot-
printing depicted above a restriction map of the -1885/+205 bp PDPN 5'-genomic region. These were: probeEB (bp -1169 to -
646), probe(-571) (bp -857 to -571), probe(-360) (bp -666 to -360), probeBM (bp -649 to -385), probeSB (bp -498 to -85), 
probeSA (bp -261 to +31), and probeBX (bp -89 to +171). Asterisks indicate the positions of radioactive labeling as described in 
the experimental procedures section. Six of the probes analyze the coding DNA strand, whereas probe BM tracks the noncod-
ing strand. B) DNaseI footprinting of probes using MG63 and Saos-2 nuclear cell extracts. End-labeled restriction fragments 
were incubated alone (Control) or with MG63 or Saos-2 cell nuclear extracts prior to digestion with DNase I. Footprinting 
was carried out in the sense and antisense direction. A sequencing reaction of the same region was run in parallel for exact size 
assignment of the protected regions. Protected sequences are indicated with single lines. Arrowheads denote sites hypersensitive 
to DNaseI.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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using eight double stranded DNA oligonucleotides span-
ning the DNase I footprint regions (Table 1). Probes alone
produced no shifted bands (data not shown). Probes fp7,
fp5, fp2 and fp1 produced a similar pattern of low-mobil-
ity DNA-protein binding (complexes I – III) when adding
nuclear extract of MG63 cells (Fig. 4, lanes -). The same
bands became faintly visible with Saos-2 extracts except
for probe fp7, which did not show complexes I and II.
Consistent with the footprints, oligos fp6 and fp4 bound
nuclear proteins strongly from MG63, but weak from
Saos-2 cells (Fig. 4, lanes -). Although covering a broad
footprint region, probe fp4 only yielded a binding pattern
of several rapidly migrating proteins, and fp8 and fp3 did
not reveal significant DNA-protein complexes (data not
shown).
Specificity of the gel shifted bands was demonstrated by
competition assays in which nuclear extracts were prein-
cubated with a 100-molar excess of unlabeled specific
(Fig. 4, lanes s) or unrelated probe (Fig. 4, lanes ns) as
competitor. As all bands of the gel shifts were eliminated
or attenuated by excess of unlabeled probe, these moieties
may bind the respective oligos in a manner requiring con-
comitant association. A computer analysis revealed con-
sensus motifs for transcription factors NF-1 (fp7, fp6), C/
EBP-α (fp5, fp4), HNF-3 (fp4), Oct-1 (fp4) and AP-4
(fp1) in the applied probes. However, a panel of antibod-
ies against these factors did not interfere with the observed
low molecular weight DNA-protein complexes in super-
shift assays (data not shown). Nonetheless, these data
suggested the presence of several sequence-specific pro-
teins bound to the proximal PDPN promoter in MG63
cells.
Sp proteins bind to fp7, fp5, fp2 and fp1in the PDPN 
promoter
Probes fp7, fp5, fp2 and fp1 contained GC-rich regions
exhibiting high homology to the consensus Sp1-binding
motif. To test the binding of Sp-proteins to these ele-
ments, supershift analyses with anti-Sp1 and anti-Sp3
antibodies were performed. When anti-Sp1 antibody was
added, complex I disappeared in favor of a supershifted
band, which showed the predominant contribution of
Sp1 (Fig. 5A, lanes Sp1). Addition of anti-Sp3 antibody
blocked protein-DNA binding, which resulted in loss of
complex II, whereas no supershifted complex appeared
(Fig. 5A, lanes Sp3). When used together, Sp1 and Sp3
antibodies supershifted or inhibited both complexes (Fig.
5A, lanes Sp1+Sp3). To further test whether the core Sp1
sequence was required for binding of nuclear proteins, gel
shift assays with the same oligonucleotide probes, but
mutated at residues known to be critical for Sp-binding
(Table 1), were performed with nuclear extracts of MG63
cells. The mutant oligos failed to form the observed com-
plexes, indicating that the chosen mutations were suffi-
EMSA analysis of footprint regions Figure 4
EMSA analysis of footprint regions. Sequence-specific 
proteins bound to oligos fp1, fp2, fp5 and fp7 of the human 
PDPN promoter. Nuclear extracts from MG63 and Saos-2 
cells were incubated with 32P end-labeled double-stranded 
oligonucleotides, in the absence (-) or presence of a 100-fold 
molar excess of unlabeled specific (s) and unspecific (ns) oli-
gonucleotide, as described in the "Methods" section. As 
unspecific probes, Oct-1 (fp1, fp2, fp5, fp7) or AP-4 (fp4 and 
fp6) consensus oligos were applied. Arrows denote the bands 
of altered mobility resulting from the interactions of nuclear 
proteins with the oligonucleotides.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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cient to eliminate the binding capacities of these sites (Fig.
5B). These studies demonstrated that four elements
within the PDPN promoter, herewith designated Sp.4 –
Sp.1, bound Sp1/Sp3 proteins from MG63 and also
weakly from Saos-2 cells. The results furthermore indi-
cated that Sp1 and Sp3 were not bound coordinately to
the DNA stretches, since the anti-Sp1 antibody did not
shift Sp3-DNA complexes and vice versa. This suggested
that Sp1 and Sp3 occupied the same or overlapping sites
of the PDPN promoter.
GC boxes Sp.4 and Sp.2 are essential for PDPN promoter 
activity
To assess the functional role of Sp binding elements Sp.4
– Sp.1, PCR-directed mutagenesis was performed at the
same residues that had blocked Sp1/Sp3 binding in gel
shift assays and were tested for their reporter activity. The
four Sp binding sites were altered individually and in
combination (Fig. 5C), and mutations were introduced
into the promoter luciferase variant -857/+171 that sup-
ported basal PDPN transcription. The transactivation pat-
tern was similar for MG63 and Saos-2 cells, indicating that
Sp1/Sp3 promotion took place through the same ele-
ments in both cell lines (Fig. 5D). The utmost relevance
was seen for Sp-binding site Sp.2 at bp -100/-95, showing
an activity reduction by 73% in MG63 and by 52% in
Saos-2 cells upon mutation. Deletion of Sp-binding site
Sp.4 at bp -700/-696 decreased luciferase activity by 57%
in MG63 and by 16% in Saos-2 cells, whereas mutation of
Sp-binding site Sp.3 (bp -570/-564) did not alter luci-
ferase activity substantially. Mutation of site Sp.1 (bp -48/
-43) lead to a slight activating trend, while combined
mutation of all four sites reduced activity to more than
80% in both cell lines. Taken together, these data sug-
gested that Sp-binding sites Sp.4 and Sp.2 alone, but espe-
cially in concert, were central regulatory elements
necessary for constitutive PDPN promoter activity in both
MG63 and Saos-2 cells, whereas Sp.3 and Sp.1 provided
no single activating importance.
Stimulatory Sp1 and repressive Sp3 coordinatively activate 
the PDPN promoter
To directly confirm the effect of Sp1 and Sp3 on PDPN
promoter activation, bp -857/+171 wild-type promoter
luciferase construct was cotransfected with increasing
amounts of CMV-promoter driven Sp1 and Sp3 expres-
sion plasmids alone and in combination into MG63 and
Saos-2 cells (Fig. 6A). In both cell types, Sp1 overexpres-
sion resulted in a weak but dose dependent stimulation of
luciferase activity with 1.8-fold induction in MG63 and
1.6-fold induction in Saos-2 cells relative to Sp1 mock-
transfected cells. Similarly, Sp3 overexpression lead to a
1.4-fold and 1.8-fold induction in MG63 and Saos-2 cells,
respectively. When both factors were coexpressed, no fur-
ther activation above 1.8-fold promoter activity was seen.
In contrast, luciferase activity of the combined mutational
variant Sp.4-1mut was not altered in these experiments.
These results suggested that Sp1 and Sp3 were able to
stimulate PDPN transcription through Sp1/Sp3 binding
sites in the proximal promoter region independently.
To confirm the effect of Sp1 and Sp3 on the activity of
endogenous PDPN gene expression in MG63 and Saos-2
cells, real-time PCR was performed after transfection with
Sp1- and Sp3-expression plasmids. The results corre-
sponded to the observed potency of the respective factors
to stimulate promoter activity. Podoplanin mRNA con-
tents were clearly increased by overexpressed Sp1 and Sp3
(Fig. 6B). Overexpression of both, Sp1 and Sp3, did not
further change mRNA levels in MG63 cells but strongly
increased them in Saos-2 cells. These results showed that
Sp1 and Sp3 indeed were able to upregulate podoplanin
expression.
The roles of Sp1/Sp3 function on the PDPN  promoter
were more clearly established in Drosophila  SL2 cells,
which lack endogenous Sp-proteins. Drosophila-specific
pPac-Sp1 and pPac-Sp3 expression plasmids were cotrans-
fected with the wild-type and Sp-site mutant promoter
variant Sp.4-1mut (Fig. 6C) and fold promoter activation
versus pPac-empty transfections was evaluated. Cotrans-
fection of Sp1 lead to a 16-fold luciferase activity increase
of the wild-type promoter. In contrast to the results seen
with MG63 and Saos-2 cells, overexpression of Sp3
reduced promoter activity 8-fold, which discovered a
strong repressive action of solely present Sp3. Neverthe-
less, coexpression of both, Sp1 and Sp3, further increased
promoter activity up to 21-fold. Since Sp1 activity was not
decreased in the presence of pPac-Sp3, Sp3 seemingly did
not compete with Sp1 for binding to the same site. The
same effects were visible on a reduced level with mutant
variant Sp.4-1mut and pGL3-Basic, indicating back-
ground activity of these constructs. Basically, these results
suggested opposed action of single Sp1 or Sp3 on the
PDPN promoter, while presence of both factors caused a
concerted activation.
Mutation of site Sp.1 at bp -48/-43 (Sp.1mut) showed a
slight increase in promoter activity (Fig. 5D), which corre-
sponded to lowered activity of bp -76/+171 versus bp -38/
+171 deletion construct (Fig. 2C). In order to explore a
potential repressive role of Sp3 on this site, reporter con-
structs bp -76/+171 and -38/+171 were cotransfected with
Sp1 and Sp3 expression plasmids and the multiple of pro-
moter activation was determined (Fig. 6D). Consistently
with luciferase reporter assays (Fig. 2C), construct -38/
+171 conferred a roughly 2-fold higher promoter activity
than -76/+171 in both cell lines (data not shown). Sp1
activated both constructs up to 1.4-fold in both cell lines.
Consistent with the overexpression studies shown in Fig.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Sp1 and Sp3 interact with the proximal PDPN promoter in vitro and in vivo Figure 5
Sp1 and Sp3 interact with the proximal PDPN promoter in vitro and in vivo. A) Supershifts were performed by incu-
bating nuclear proteins either with anti-Sp1 antibody or with anti-Sp3 antibody, both antibodies together, or non immune IgG 
before addition of probe. Anti-Sp1 antibody supershifted complex I (ss-Sp1), while anti-Sp3 antibody specifically blocked the 
formation of protein-DNA complex II. B) Mutation of Sp binding sites (mut) abolished the binding complexes I and II versus the 
wild-type probe (wt) with nuclear extracts from MG63 cells. The mutated oligonucleotides used in this study are listed in Table 
1. C) Deletion mutants of the four Sp-elements in the PDPN promoter. The sequences above the Wild-Type construct exhibit 
the core sequences of the Sp binding sites. Above each mutation construct, the respective mutated nucleotides are drawn in 
bold italics. In construct Sp.4-1mut, all four Sp elements are mutated. D) The wild type reporter construct and five mutation 
constructs were transiently transfected into MG63 and Saos-2 cells. Firefly luciferase values were divided by those of the inter-
nal control Renilla luciferase to represent the absolute promoter activity. Stars indicate the statistical difference of the pro-
moter activities between the unmutated and mutated transfection experiments. *, p < 0.05; **, p < 0.01.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Sp1 and Sp3 are critically involved in PDPN promoter activation Figure 6
Sp1 and Sp3 are critically involved in PDPN promoter activation. A) Cotransfection of the core promoter construct 
(-857/+171) without (Wild-Type) and with Sp-binding site mutations (Mutant) using increasing amounts of pCMV-Sp1 and 
pMCS-Sp3 or a combination of both expression plasmids along with pRL-TK into MG63 and Saos-2 cells. The total amount of 
expression plasmids was filled to 0.17 µg with empty vector. Luciferase values were normalized to the internal control Renilla 
luciferase and fold-induction versus mock-transfected cells was evaluated. B) Real-time PCR analysis of podoplanin transcrip-
tion in MG63 and Saos-2 cells upon transfection with Sp1 and Sp3 expression vectors. Transcript levels are relative to GAPDH 
mRNA content. The average ± S.D. from two independent experiments performed in triplicates is shown. C) Drosophila SL2 
cells were transiently transfected with Wild-Type promoter, Sp.4-1mut construct and pGL3-Basic. Cells were cotransfected 
with Drosophila expression vectors pPac-empty, pPac-Sp1, pPac-Sp3, or both. Fold promoter activation versus pPac-empty 
transfections was evaluated. The average ± S.D. from three independent experiments performed in triplicates is shown. D) The 
role of Sp.1 for PDPN promoter activity. Cotransfection of the shortened promoter constructs (-76/+171) and (-38/+171) with 
pCMV-Sp1 or pMCS-Sp3 along with pRL-TK into MG63 and Saos-2 cells. The statistical difference of the promoter activity in 
all panels is shown against mock-transfected cells. *, p < 0.05, **, p < 0.01, ***, p < 0.001.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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6A, Sp3 overexpression did not exert repressive effects on
the bp -76/+171 construct. In MG63 cells, activity of the
bp -76/+171 construct was not altered by additional Sp3-
overexpression, while it even increased in Saos-2 cells.
Therefore, we were not able to demonstrate a repressive
Sp3 action on site Sp.1. We rather suggest a suppressive
interaction of Sp-proteins bound to Sp.1 in combination
with another yet unknown factor located more down-
stream from bp -38, which is abolished through shorten-
ing of the promoter or by deletion mutation of site Sp.1.
A more detailed analysis of this site will be of future inter-
est.
Conclusively, these results clearly demonstrated the piv-
otal importance of Sp1 and the auxiliary importance of
Sp3 for basal transactivation of the PDPN promoter.
Saos-2 cells exhibit reduced nuclear Sp protein levels and 
low Sp protein amounts bound to the PDPN promoter in 
vivo
To further clarify the transcriptional difference between
MG63 and Saos-2 cells, we focussed on the observation
that nuclear extracts of Saos-2 cells produced weak Sp1/
Sp3 EMSA signals compared to those derived with MG63
extracts (Fig. 5B). A comparative Western blot analysis
showed little difference in overall Sp1/Sp3 protein con-
tents between MG63 and Saos-2 cells (Fig. 7A, lanes 1 and
2, and densitometric analysis), whereas nuclear Sp1 and
Sp3 amounts were lowered about 82 and 88%, respec-
tively, in Saos-2 versus MG63 cells (Fig. 7A, lane 3 and 4,
and densitometric analyis).
In order to assess whether Sp proteins bound to the iden-
tified DNA stretches in vivo, chromatin immunoprecipita-
tions were performed using antibodies against Sp1 and
Sp3 and crosslinked chromatin from MG63 and Saos-2
cells (Fig. 7B). After immunoprecipitation with anti-Sp1
antibody, extensive PCR amplifications from the Sp-bind-
ing sites relative to control input DNA were seen with
MG63 derived chromatin (Fig. 7B, upper panels). In con-
trast, Saos-2 cells exhibited weak amplification levels ver-
sus input DNA (Fig. 7B, lower panels), which indicated
low Sp1 occupation of these positions. PCRs from anti-
Sp3 antibody precipitated chromatin resulted in overall
weaker amplification results (Fig. 7C), which corre-
sponded to the low DNA-bound Sp3 amounts seen in
EMSAs (Fig. 5A). Site Sp.4 was stronger occupied by Sp3
in MG63 than in Saos-2 cells, while in both cell types site
Sp.3 was scarcely occupied by Sp3. Sites Sp.2 and Sp.1
were acquainted with Sp3 to an equal, yet moderate extent
in both cell lines. These data raised the possibility that
drastically reduced nuclear Sp protein concentrations
were responsible for weak PDPN  promoter activity in
Saos-2 compared to MG63 cells.
The PDPN promoter is strongly methylated in MG63 but 
not in Saos-2 cells
To further unravel the transcriptional difference between
podoplanin expression in MG63 and Saos-2 cells, epige-
netic effects were considered. The PDPN promoter con-
tained a high CG content which provided putative
methylation sites. Correspondingly, two CpG islands
were detected [28], one encompassing bp -183/+16 that
spanned the core promoter, and the other stretching from
bp +76 to +517, including exon 1 (bp +203 to +267) plus
249 bp of intron 1 (Fig. 8A). A PstI genomic DNA-frag-
ment that covered bp -2799 to +1191 of the PDPN pro-
moter and gene was used to analyze a potential
methylation-sensitive restriction pattern. The fragment
contained 121 palindromic CpG dinucleotides, sixteen of
which represented isoschizomeric HpaII/MspI restriction
sites accumulating in three clusters. Five Southern blotting
probes were situated beside and between these clusters
(Fig. 8A). Digestion of genomic DNA with PstI alone pro-
duced the anticipated 3990 bp fragment (Fig. 8B, lanes P),
and double-digestion with PstI plus methylation-insensi-
tive enzyme MspI yielded the smallest possible fragments
(1047, 1044, 399, 257 and 700 bp, respectively) (Fig. 8B,
lanes M). When using PstI together with methylation-sen-
sitive HpaII, complete digested bands were observed with
Saos-2 derived genomic DNA, while in MG63 cells the
distal probes P/B and F2/K mainly detected undigested
2.2 and 2.7 kb bands besides small portions of complete
digested fragments (Fig. 8B, lanes H). Moreover, with
probe F5/Bs only the digestion resistant 2.7 kb fragment
was visible. These results indicated strong methylation of
region bp -2799/-464 in MG63 cells, while it was totally
unmethylated in Saos-2 cells.
To clarify the PDPN  promoter methylation status in
MG63 cells in detail, genomic DNA was analyzed by
bisulfite sequencing. Genomic DNA was treated with
sodium bisulfite under conditions where cytosines are
converted to uracils, while methylated cytosines remain
unmodified [29]. Three PCR reactions were set to inspect
the methylation level of the HpaII/MspI restriction site
clusters (Fig. 8C). When PCR1 (bp -198 to +131) was con-
sidered, the methylation level was found to be less than
5%. With PCR2 (bp -759 to -485), except CpG sites 32
and 33 that were methylated to 25% and 50%, respec-
tively, all CpG sites were fully methylated. PCR3 (bp -
2005 to -1572) comprised three CpG sites, which were
highly (site 8 to 86%, site 9 to 57%) or fully (site 10)
methylated. The observed methylation pattern corre-
sponded to the fragmentation results seen in Southern
blotting and identified a highly methylated DNA status of
the PDPN promoter upstream of bp -485 in MG63 cells.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
Page 13 of 24
(page number not for citation purposes)
Sp1/3 cellular versus nuclear levels and in vivo occupation of the PDPN promoter Figure 7
Sp1/3 cellular versus nuclear levels and in vivo occupation of the PDPN promoter. A) Immunoblot analysis and den-
sitometric quantification of Sp1 and Sp3 protein contents in MG63 and Saos-2 cell lysates and nuclear extracts. Total cellular 
protein and nuclear extracts from MG63 and Saos-2 cells were resolved on 10% SDS-PAGE and blotted onto nitrocellulose. 
Levels of endogenous Sp1 and Sp3 proteins were determined by probing the blots with anti-Sp1 and anti-Sp3 antibodies, 
respectively. Sp1 shows a 105 kDa band, whereas Sp3 shows two bands at 120 and 75 kDa. Blots were reprobed with anti-
GAPDH and anti-TFIID antibodies as loading control. After densitometric evaluation, Sp1/Sp3 levels were normalized to 
respective GAPDH and TFIID levels from the same blot. Data are given as the mean ± S.D. of samples of the experiment 
repeated three times. B) and C) Association of Sp1 and Sp3 to the PDPN promoter in vivo. Formaldehyde crosslinked chroma-
tin was precipitated with an antibody specific for Sp1 (panel B) and Sp3 (panel C). PCRs were performed with primer pairs 
flanking the four Sp binding sites. L, 100 bp DNA ladder; +, immunoprecipitation with anti-Sp1 or anti-Sp3 antibody; co, precip-
itation control with unspecific rabbit IgG; -, negative control without antibody; Input, dilution series of control input DNA; no 
DNA, PCR negative control.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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The distal PDPN promoter is fully methylated in MG63 but non-methylated in Saos-2 cells Figure 8
The distal PDPN promoter is fully methylated in MG63 but non-methylated in Saos-2 cells. A) Schematic repre-
sentation of HpaII/MspI binding sites and CpG islands within a PstI genomic DNA fragment spanning from bp -2799 to +1191 of 
the PDPN promoter with respect to the transcription initiation start site (arrow at +1). The graphs depict the CpG blot cre-
ated by the EMBOSS program. Exon 1 is drawn as an open box in the sequence. HpaII/MspI recognition sites are represented 
by vertical lines along the sequence, and CpG islands are indicated as empty boxes above. Probes used for Southern blot anal-
ysis and stretches that were amplified after bisulfite genomic DNA sequencing are indicated as black bars and lines, respec-
tively, below the sequence. B) Genomic DNA from MG63 and Saos-2 cells was double-digested with PstI, and with PstI in 
combination with the methylation-sensitive restriction enzyme HpaII or the methylation-insensitive restriction enzyme MspI. 
DNA then was fractionated by agarose gel electrophoresis followed by Southern blotting using the five DNA probes depicted 
in Fig. 8A. C) CpG methylation pattern of the PDPN promoter and of exonic and intronic CpG islands in MG63 cells as deter-
mined by sodium bisulfite genomic DNA sequencing. The CpG number indicates the order of the CpG site inside the PstI 
genomic fragment, and the CpG position denotes its position in relation to the transcription start site. The color-tone of the 
circle reflects the degree of methylation: black: 100%, dark blue: 99-67% blue: 66-34%, light blue: 33-1%, white: 0% methylation. 
Asterisks indicate CpG motifs that are part of a HpaII/MspI restriction digest site.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
Page 15 of 24
(page number not for citation purposes)
Methylation of GC boxes Sp.4 and Sp.2 does not affect Sp-
protein binding
In MG63 cells, the heavy methylation pattern stretched
accross functional Sp1/Sp3 binding site Sp.4 (CpG
number 23, Fig. 8C), whereas binding site Sp.2 was situ-
ated in the virtually unmethylated proximal promoter
region (CpG number 52, Fig. 8C). To test whether this sit-
uation gave rise to modulatory binding of Sp-proteins, we
compared the capabilities of respective oligos fp7 (site
Sp.4) and fp2 (site Sp.2) to inhibit the formation of Sp1-
/Sp3-DNA complexes with nuclear extracts of MG63 cells
in methylated as well as unmethylated form. As shown in
Fig. 9A, protein-DNA complexes were competed by
increasing concentrations of both, methylated and
unmethylated forms of probes fp7 and fp2 to an equal
extent. These data suggested that Sp binding sites Sp.4 and
Sp.2 were able to interact with Sp1/Sp3 even when meth-
ylated.
Distal promoter methylation enhances PDPN promoter 
activity
To further test the role of DNA methylation and histone
acetylation for control of podoplanin expression in vivo,
MG63 and Saos-2 cells were treated with methyltrans-
ferase inhibitor 5-aza-2'-deoxycytidine (5-azaCdR) and
histone deacetylase inhibitor trichostatin A (TSA). Cell
viability was tested by increasing concentrations of the
agents over a cultivation period of 3 days to exclude
mRNA downregulation effects upon apoptosis. Then, cells
were treated either with 5-azaCdR and TSA alone or with
5-azaCdR followed by TSA, and podoplanin mRNA
amounts were analyzed by quantitative Northern blot
analysis. In Saos-2 cells, the drugs were not able to initiate
de novo synthesis of podoplanin mRNA (data not shown),
which demonstrated that lack of PDPN transcription was
not under epigenetic control. In MG63 cells, variations of
both podoplanin mRNA bands seen in Northern blot
were evaluated (Fig. 9B). 5-azaCdR treatment did not
change  PDPN  transcription levels when compared to
untreated cells, while 0.6 µM TSA lead to a respective 28%
and 48% reduction of PDPN transcription. Moreover, a
combination of 1 µM 5-azaCdR and 0.6 µM TSA
decreased PDPN transcription by 50% and 57%, respec-
tively. These data indicated that in MG63 cells, in vivo
modification of the promoter chromatin structure
through combined demethylation and histone hyper-
acetylation rather repressed than enhanced PDPN tran-
scription.
To investigate whether methylation of the distal PDPN
promoter portion indeed assisted activation of gene tran-
scription, further luciferase reporter gene assays were per-
formed (Fig. 9C). Complete in vitro methylation of the
promoter plasmids pGL3(-1885/+171) and pGL3(-857/
+171) lead to more than 90% loss of promoter activity in
MG63 and Saos-2 cells, indicating that the vectors were
susceptible to inhibition by methylation. To further assess
promoter activity upon selective methylation of defined
promoter regions, fragments bp -1885/+171 and -857/
+171, or fragments bp -1885/-189 and -825/-189, which
comprised the region that wasmethylated in vivo in MG63
cells, were generated by restriction digest with SacI/XhoI or
SacI/ApaI, respectively (Fig. 9C). The four fragments were
methylated by SssI methylase or mock-methylated, reli-
gated into the unmethylated reporter plasmid backbone
and transfected into MG63 and Saos-2 cells. In vitro meth-
ylation of all promoter CpGs until bp +171 revealed a
weak trend towards transcriptional deactivation being
more pronounced in Saos-2 than in MG63 cells (Fig. 9C).
This result supported the observation that methylation of
site Sp1.2 did not affect Sp1/Sp3 binding (Fig. 9A). Con-
versely, selective methylation of CpG sites upstream of bp
-189 containing 35 or 24 CpG sites, respectively, led to
considerable promoter activity increase versus mock
methylated constructs, which added up to more than 40%
and 30% in MG63 and to more than 25% and 60% in
Saos-2 cells. These data indicated that a putative methyla-
tion-dependent enhancement mechanism, possibly effi-
ciently altering chromatin structure, was able to act on
PDPN transcription.
Discussion
The present study provides a comprehensive analysis of
the PDPN gene promoter region in human osteoblast-like
cell lines. It was our aim to clarify which mechanisms
account for cell type-specific expression of podoplanin in
MG63 versus Saos-2 cells, as direct regulators of PDPN
transcription in human systems have not been elucidated
yet. We show that PDPN transcription was initiated from
several start sites within 97 bp, the most 3' located tran-
script of which corresponded to the major initiation site
in the murine and rat gene [24]. Generally, the PDPN pro-
moter seems to belong to the group of regulative genomic
entities which are characterized by the absence of a con-
sensus TATA and CAAT box, by a high GC content and
multiple potential binding sites for the transcription fac-
tor Sp1. Such genes are usually either ubiquitously
expressed (e.g. housekeeping genes) or are growth related,
as for instance dihydrofolate reductase [30]. Nonetheless,
genes possessing these features have been identified to be
expressed in tissue-specific manner, e.g. RAGE [31] or
thioredoxin reductase 1 [32]. The chosen promoter frag-
ments indeed conferred intense transcriptional activity in
MG63 but not in Saos-2 cells, indicating the presence of
differentially bound positive regulators.
Functional analyses of the proximal PDPN  promoter
revealed four potential Sp1/Sp3-binding sites and the key
roles of two of these at bp -700/-696 (site Sp.4) and bp -
100/-95 bp (site Sp.2) for constitutive activation in both,BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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The role of PDPN promoter methylation in MG63 cells Figure 9
The role of PDPN promoter methylation in MG63 cells. A) EMSA competition experiments were performed using cold 
methylated and unmethylated fp7 (site Sp.4) and fp2 (site Sp.2) probe as competitors. Competitors were used at 50-fold excess 
at the small end of the triangle and at 100-fold excess at its large end. B) Densitometric quantification of both podoplanin 
mRNA transcripts isolated from MG63 cells which had been treated with 5-azaCdR and TSA alone or in combination. The 
abundance of podoplanin transcripts was normalized to GAPDH transcripts in the same samples. The data are given as the 
mean ± S.D. of triplicate samples of the experiment repeated twice. The statistical analysis denotes the significant difference 
between non-treated MG63 cells and cells treated with 5-azaCdR or/and TSA. *, p < 0.05, ***, p < 0.001. C) Whole pGL3-con-
structs or selected inserts thereof were methylated or mock-methylated in vitro and transfected into MG63 and Saos-2 cells. 
Results are given as luciferase activity normalized to cotransfected pRL-TK activity. The experiment was repeated three times 
independently in triplicates. The statistical analysis denotes the significant difference between mock methylated (hatched) and 
respective methylated (black) constructs. *, p < 0.05, **, p < 0.01, ***, p < 0.001.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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MG63 as well as Saos-2 cells. Sp1 has been the first mam-
malian transcription factor to be cloned [33] and invaria-
bly activates transcription [34], whereas Sp3, dependent
on the position of the element within the intact promoter
and the number of Sp binding sites [35], is able to either
enhance or suppress transcription. Sp1 and Sp3 have been
described to be involved in the regulation of osteoblast-
specific genes like beta 5 integrin [36], osteocalcin [37], or
alpha2 (XI) collagen (COL11A2) [38] yet. The role of the
more distal site Sp.4, which was conserved in the rat pro-
moter, has not been described elsewhere, whereas site
Sp.3 was not conserved. Binding site Sp.2 was conserved
between human, rodent and bos tauris PDPN sequence,
and its activating role has previously been demonstrated
in rat type I alveolar cells [24]. Also binding site Sp.1 was
conserved between humans and rodents.
The effect of Sp protein transactivation on the PDPN pro-
moter was seen pronounced in Drosophila SL2 cells. Inter-
estingly, Sp1 and Sp3 seemed to regulate PDPN
transcription in a contrarious, yet overall cooperative
manner. The results demonstrated a strong positive effect
of Sp1 on the PDPN  promoter, whereas Sp3 acted as
repressor. In MG63 and Saos-2 cells, a repressive effect of
Sp3 was not observed, which, however, may be masked by
concurring Sp1-binding through endogenously present
Sp1. On the other hand, Sp protein overexpression effects
were not very pronounced in these cells, presumably by
the same reason of intrinsic Sp protein background. One
could argue that Sp1 or Sp3 were not essentially impor-
tant to control PDPN promoter activity, but when consid-
ering the generally low transfection rates of less than 10%
in MG63 cells, an overall 1.8-fold promoter activation
corresponded to a 12-fold induction of promoter activity
if all cells were transfected. Sp3 stimulated the PDPN pro-
moter in Saos-2 cells stronger than in MG63 cells, which
can be explained through a more potent effect due to the
lowered nuclear Sp3 amounts as seen from Western blot-
ting. Additionally, this effect might have resulted from
generally better transfection efficiencies in Saos-2 cells.
Real-time PCR analyses then convincingly demonstrated
the effect of Sp-proteins on endogenous PDPN  gene
expression in both cell lines. We therefore assume that a
balance between cooperatively bound Sp1 and Sp3 tightly
regulates activity of the PDPN promoter in these osteob-
lastic cell lines.
Sp1/Sp3 site EMSA analyses suggested that they were
occupied by regulators mainly present in MG63, but not
in Saos-2 cells. The faint Sp1/Sp3-DNA interactions of
Saos-2 nuclear extracts may be due to several reasons:
Firstly, nuclear Sp-proteins can be inactivated by dephos-
phorylation [39], or Sp-proteins may be present in the
nuclei, but in very low concentrations. Indeed, Western
blotting experiments pointed out that nuclear Sp1/Sp3
protein amounts were distinctively lower in Saos-2 than
in MG63 cells, and chromatin immunoprecipitations
confirmed the low in vivo occupancy of Sp binding sites in
Saos-2 cells. Hence, these low Sp-protein concentrations
might be insufficient to drive PDPN  transcription and
strikingly would explain the lack of podoplanin mRNA in
Saos-2 cells. In MG63 cells, nuclear Sp1/Sp3 quantities
were highly abundant, which could rely on increased
nuclear Sp protein translocation and/or a decreased efflux
of Sp proteins out of the nuclei [39]. Consistent with our
results, hyperoxia treatment of murine lung epithelial
cells caused an increased nuclear abundance of Sp1 that
lead to enhanced expression of podoplanin/T1α [40].
Besides control through nuclear concentration thresholds,
Sp-mediated transcriptional changes can be mediated by
interactions with additional transcription factors, such as
cAMP [41] or NFκB [42]. When reducing the PDPN pro-
moter stretch from bp -1104/+171 to bp -854/+171, tran-
scriptional activity decreased about more than 50%. In
DNaseI footprintings, however, no protected region could
be detected in this region. Proteins attaching to this region
might need concurrent binding of Sp1/Sp3 or of other fac-
tors more downstream. Such interaction mode without
direct DNA contact could also explain the divergent
results of DNaseI footprints and EMSA analyses at regions
fp8, fp6, fp4 and fp3. In contrast to the reproducible foot-
printing results, nuclear proteins binding directly to the
same motifs could not be detected in EMSAs. This result
may either be explained by the presence of low affinity
factors that rapidly dissociate from the DNA during the
assay, or the attachment of proteins to these sites may
depend on adjacent bound Sp1/Sp3-proteins and conse-
quently could not be grasped due to the restricted length
of the applied DNA probes. Consecutively, in Saos-2 cells
accessory assembly of the same activating factors would
be impossible due to lack of Sp allocation.
Moreover, despite its conservation between humans and
rodents, we could not clearly prove functionality of bind-
ing site Sp.1 through repressive Sp3. Surprisingly, the
higher promoter activity of the bp -38/+171 versus bp -76/
+171 variant, as well as of the mutational Sp.1 variant
rather seemed to result from additional interactions to a
factor located more downstream than through repressive
Sp3. Possibly, this mechanism may be a regulative to sup-
press extensive PDPN transcription. For example, interac-
tion of Sp1 with E2F has been shown to control growth
related gene transcription [43]. Studies are ongoing that
shall clarify the presence and identity of factors that are
physically associated with Sp1/Sp3 bound to sites fp7, fp2
and fp1.
Sp7/Osterix respresents an interesting Sp protein family
candidate relevant for activation of osteoblast-specificBMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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genes. It is essential for osteoblast differentiation and
bone formation [44], and its expression has been detected
in MG63 [45] as well as Saos-2 cells [38]. Its potential role
for PDPN promoter activation may be of interest and shall
be clarified in future studies. As in murine and human
osteosarcoma cells, on the other hand, Sp7/Osterix
expression has been detected to be reduced versus normal
osteoblasts [46], we presume that Sp7/Osterix contents
might also be lowered in MG63 and Saos-2 osteosarcoma
cells and therefore would exert a minor effect on PDPN
promoter activation.
To unravel the transcriptional difference between MG63
and Saos-2 cells more thoroughly, potential DNA methyl-
ation of the PDPN promoter was examined. We identified
complete promoter demethylation in Saos-2 cells,
although no PDPN transcription took place. By contrast,
in MG63 cells the distal promoter part was strongly meth-
ylated, while the PDPN gene was efficiently transcribed.
This DNA modification affected the functional Sp protein
binding site Sp.4, but in vitro competition data proved
that Sp-protein binding to this site was possible even
when it was methylated. Our data therefore strongly sup-
port studies demonstrating that CpG methylation has no
effect on attachment of Sp1 [47], whereas others have
found that it diminished Sp1/Sp3 binding [48].
Chromatin modification by CpG methylation and/or his-
tone deacetylation has been linked inevitably with tran-
scriptional repression [49]. However, our data provide
evidence for a positive correlation between DNA methyl-
ation/histone modification and PDPN  transcription in
MG63 cells, as in our hands, induction of this classical
"active chromatin state" rather conferred deactivation of
gene activity. More importantly, site-specific DNA methyl-
ation by no means lead to down-modulation of promoter
activity. The theoretical possibility of a repressor binding
to the promoter and being competed by DNA methyla-
tion in MG63 cells has to be excluded, because demethyl-
ated PDPN promoter (i.e. the pGL3-promoter luciferase
constructs) was highly active in MG63 cells. In agreement
with that, no repressor-DNA interactions could be identi-
fied in Saos-2 cells. The mechanistic principle underlying
the observed phenomenon could be diverse: When treat-
ing MG63 cells with 5-azaCdR in combination with TSA,
consecutive conformational changes of chromatin may
hinder Sp-protein binding and lead to downregulation of
PDPN transcription. Secondly, it is tempting to hypothe-
size that methylation-dependent protein-DNA interac-
tions being able to stimulate transcription may exist
(methylation dependent factor MDF, Fig. 10). For exam-
ple, the zinc finger protein Kaiso has been found to bind
to both, methylated and sequence-specific recognition
sites, fulfilling repressive [50] or activating functions [51].
Here, we identify a completely different methylation sce-
nario than has been observed in brain and lung alveolar
type I cells of the rat [25]. In these cells, DNA methylation
was detected at key site Sp.2 under podoplanin/T1α non-
expressing conditions, whereas its transcription could be
initiated by addition of methyltransferase-inhibitor.
These findings may indicate that the switch between tran-
scriptional silencing and expression of podoplanin in dif-
ferent tissues/organs could depend on varying epigenetic
phenomena, apparently driven by basal Sp1/Sp3 activa-
tion at conserved promoter sites. Studies using additional
cell lines that constitutively or upon stimulation express
podoplanin are ongoing to better understand the effect of
methylation on this type of promoter. Preliminary data
are pointing at again different methylation patterns in
other cell lines. Moreover, altered histone modification
patterns of the PDPN promoter chromatin have to be con-
sidered, as this process is intimately connected with DNA
methylation [52]. Presumably, diverse regulatory path-
ways are mediating these epigenetic patterns in different
cell types or even species.
To our knowledge, this investigation is only the second
one reporting on a certain protein exhibiting increased
transcription levels upon methylation [53]. Unlike podo-
planin, this report describes increased transcription of an
imprinted gene (Igf2) upon enhanced intragenic methyla-
tion, whereas in our study the 5' regulatory region was
affected. Similar to our findings, some studies have shown
a positive effect on gene expression when methylation
downstream of the transcriptional start site had occurred
[54], and hypermethylation of CpG islands has been
detected in actively transcribed regions of cancer cells
[55]. On the other hand, hypermethylated gene promot-
ers, generally, have been associated with inappropriate
gene silencing as an effect of selection during neoplasia
[56], which follows a primary leakiness of the cellular
repression machinery [57]. A further unexpected finding
of our study is hypomethylation of an inactive promoter.
In accordance with this, 1–2% of genes of murine fibrob-
last cultures observed in an array study were downregu-
lated through genomic demethylation [58]. Moreover,
hypomethylated inactive DNA has been detected through-
out large areas of the inactive female X chromosome and
in gene-poor genomic regions of tumour cells [56]. Reca-
pitulatory, changes in DNA methylation patterns play a
fundamental role in cancer and may regard to losses or
increases of epigenetic patterns [59]. The epigenetic event
observed in our study may have provided a selection
advantage to MG63 osteosarcoma cells and further clonal
selection, considering that podoplanin recently has been
assessed to contribute to tumour progression by circum-
venting epithelial-mesenchymal transition [22].BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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Conclusion
Conclusively, we studied the cell-type specific regulation
of podoplanin expression in human MG63 versus Saos-2
osteoblast-like osteosarcoma cells. The results are summa-
rized in the proposed activation model depicted in Figure
10.
Our findings indicate that Sp1/Sp3 members constitu-
tively bind at least to three responsive elements of the
PDPN promoter in MG63 cells in vivo, and that the activity
of the promoter primarily depends on the integrity of two
of these sites. Increased nuclear Sp1/Sp3 levels were
shown to be responsible for activation of the promoter in
MG63 versus Saos-2 cells. Additional transcription factor
complexes located even more upstream seem to up-regu-
late PDPN gene expression strongly in MG63 versus Saos-
2 cells. Analysis of the human PDPN promoter sequence
undertaken here did not detect high score binding sites for
osteoblast-specific transcription factors. However, the
possibility that such factors participate in PDPN transcrip-
tional regulation cannot be excluded, either by represent-
ing coactivators without direct DNA interaction, or by
binding to far more upstream or downstream regulatory
regions. A highly methylated chromatin conformation
present in the distal promoter in MG63, but not in Saos-2
cells, leads to auxiliary enhancement of transcriptional
activity of the PDPN gene. Our data are conflictive with
previous findings supporting a negative correlation
between methylation status and transcriptional activity of
a promoter. Studies are under way to further dissect the
mechanistic principle of regulation provided by this type
of promoter in other podoplanin expressing cell lines.
Methods
Cell culture
Human osteoblast-like osteosarcoma cell lines MG63 and
Saos-2 were obtained from American Type Culture Collec-
tion (ATCC CRL-1427 and HTB-85, respectively). Cells
were maintained at 37°C with 5% CO2 and were grown as
described in the ATCC protocol. Drosophila Schneider SL-
2 embryo cells (ATCC CRL-1963), a kind gift from Dr.
Hans Rotheneder, were maintained in Drosophila-SFM
Possible model of transcriptional control of podoplanin expression in MG63 versus Saos-2 cells Figure 10
Possible model of transcriptional control of podoplanin expression in MG63 versus Saos-2 cells. The PDPN pro-
moter is active, when, accompanied by distal hypermethylation, several factors accumulate near Sp1/Sp3 proteins bound at 
sites bp -700/-696 (Sp1.4) and bp -100/-95 (Sp1.2). A factor located downstream from bp -38 and associated with Sp1/Sp3 
bound to site Sp.1 may exert a repressive effect. The arrow indicates the major transcription start site; the small vertical bars 
indicate the CpG sites; the diamonds indicate the CpG sites analyzed in this study; fp, footprint detected protein; MDF, methyl-
ation dependent factor.BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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(Gibco) supplemented with 2 mM glutamine without
antibiotics.
Reverse transcription and Real-time PCR, Northern 
blotting and RACE
Total RNA was extracted from cells lines with TriReagent
(Molecular Research Center, Inc.). For RT-PCR analysis of
cell lines, total RNA of twelve different cell lines was tran-
scribed into cDNA using RT-for-PCR-Kit (Clontech), and
PCRs were carried out with Taq DNA Polymerase (Amer-
sham Biosciences) and the RNA-specific primers 12B1-F1
and LF3-AT, which create a 322 bp PCR fragment. For real-
time PCR, cDNA was synthesized with the Sprint Power-
Script Kit (Clontech). PCR then was performed with the
PDPN-specific primers Hs 01089982-g1 and the GAPDH-
specific primers Hs 9999905-m1 (Applied Biosystems) in
an ABI Prism 7000 Taqman. For analyzation of multiple
potential start sites, total RNA was transcribed into cDNA
by Superscript II RT (Invitrogen) using the PDPN gene
specific 3' primer hPP (+207/+178) located at the 3'-end
of the 5' untranslated region. RT-PCR was then performed
with nine 5' primers (Table I) in combination with the 3'
primer hPP (+114/+96). For Northern blotting, total RNA
was fractionated on 1.2% formaldehyde-denaturing agar-
ose gels, transferred onto a nylon membrane (Zeta-probe
GT genomic membrane, BioRad) and fixed by UV cross-
linking. Blots then were incubated with a probe covering
bp +206 to +723 of podoplanin mRNA and with a
GAPDH probe for normalization of RNA amount. Densi-
tometric quantification was perfomed with the LumiAna-
lyst 3.0 program (Roche). 5'- and 3'-RACE were performed
using respective RACE systems (Gibco) and total RNA
derived from MG63 cells. PCR products derived from
both procedures were cloned into vector pCR2.1 (Invitro-
gen) and the sequencing results of randomly picked
clones were employed to construct a map of transcrip-
tional variants.
Isolation of the PDPN promoter
The genomic BAC clone 53F6 was derived from the
Human RPCI-11 library (Research Genetics) [60]. By
Southern blotting of several restriction digests, utilizing a
unique SacII site at bp +125 as a size reference point, the
clone was assayed for containing a large portion of the 5'-
upstream region of the human PDPN gene. 4.6 kb of the
PDPN 5'-flanking region were sequenced by primer walk-
ing applying the Sanger dideoxy chain termination
method. According to these results, four subsequent PCR
primer pairs were designed, which enabled the generation
of four fragments each covering ~1.2 kb of the 5'-flanking
region, and, by the insertion of appropriate restriction
sites, stepwise cloning of the promoter. The PCR products
were cloned separately into the T/A cloning site of pCR 2.1
(Invitrogen) and subjected to sequence analysis. Potential
transcription factor binding sites were predicted using the
Alibaba and Gene Viewer programs, which employ
TRANSFAC 5.0 matrices [61] with a core similarity of 1.0
and matrix similarity 0.9. Potential CpG islands were
identified by the EMBOSS CpGplot program package
[62].
Plasmid constructs
Two PDPN promoter constructs were derived from the
original cloning procedure with 5' primers FII, FI and 3'
primer RI (Table 1). Additional deletions were prepared
using fourteen 5' primers (Table 1) in combination with
3' primer RI. PCR products were generated by standard
PCR procedure and cloned into the T/A cloning site of the
pCR 2.1 vector. 5'-flanking SacI and XhoI sites, which had
been synthesized at the upper and lower primers, were
used for unidirectional cloning of fragments upstream
from the luciferase gene into the pGL3-Basic vector
(Promega). Mutations at Sp1/Sp3 consensus sites were
introduced using mutation primers (Table 1) and the
QuikChange II site-directed mutagenesis kit (Stratagene).
A Sp1 expression plasmid was derived from cDNA clone
Nr. 7030772 (ATCC, Molecular Genomics Resources),
and a loss of function mutation in this clone was corrected
by site directed mutagenesis as described above. After
digestion with XmaI, the Sp1 coding region was cloned
into the correct reading-frame of expression vector pIRES-
neo (Stratagene), which contains a CMV promoter.
pMCS-Sp3, pPac-Sp1, pPac-Sp3 and pPac-empty were a
kind gift from Dr. Guntram Suske, Marburg, Germany
[63]. All DNA constructs were purified using Endo-free
Midiprep Kit (Promega), and correct identities were con-
firmed by sequencing.
Transient transfections and luciferase reporter assay
MG63 and Saos-2 cells were transiently transfected in 24-
wells using Effectene transfection reagent (Qiagen), as rec-
ommended by the manufacturer. For transfections, 0.05
pmol of each reporter pGL3-promoter construct or the
external control vector pGL3-Control (Promega) were
used per well. In each well, 0.005 pmol thymidine kinase
driven Renilla luciferase vector pRL-TK (Promega) served
as an internal standard for transfection efficiency. For tri-
ple-transfection experiments, wells were transfected with
0.1  µg of reporter constructs and 0.01 µg of pRL-TK
together with increasing amounts of Sp1 or Sp3 expres-
sion plasmid. Luciferase activities were normalized for
transfection efficiency according to Renilla activities. For
testing effects of Sp-protein overexpression on PDPN tran-
scription, MG63 and Saos-2 cells were transfected in 12-
wells with 0.6 µg pCMV-Sp1 or pMCS-Sp3, or with 0.3 µg
of each vector. SL-2 Drosophila cells were transiently trans-
fected in 12-wells with 0.25 µg of pPac vectors together
with 0.25 µg of luciferase reporter using FuGene6 (Roche)
according to the manufacturer's recommendations. After
48 h, cells were lysed in 1 × passive lysis buffer and luci-BMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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ferase activities were measured by the Dual Luciferase
Reporter Assay System (Promega) per the manufacturer's
instructions. When using single Luciferase signals, activi-
ties were normalized to protein amounts of the lysates as
determined by BCA assay (Pierce). Measurements were
made using a Lumat LB9507 luminometer (EG&G
Berthold).
Preparation of nuclear extracts
Nuclear extracts were prepared from MG63 and Saos-2
cells with minor variations of the method of Dignam et al.
[64]. Briefly, cells were washed twice with ice-cold phos-
phat-buffered saline, scraped off in PBS and centrifuged 5
min at 1500 × g at 4°C. Cells were resuspended in buffer
A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, 0.5 mM PMSF), left on ice for 20 min and
were lyzed by passing them ten times through a 22 gauge
needle. The nuclei were recovered by centrifugation for 6
min at 4500 × g, washed with buffer A, and the nuclear
proteins were extracted with high salt buffer B (20 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM
EDTA, 25% glycerol, 0.5 mM DTT and 0.5 mM PMSF) on
a rotating wheel for 30 min at 4°C. Extracts were centi-
fuged for 15 min at 10000 g, and supernatants were stored
in aliquots at -78°C until use. Protein concentrations were
measured by BCA protein assay (Pierce) giving typical
protein yields of 3 – 4 µg/µl.
DNaseI footprint analysis
Footprinting experiments were performed with the Core
Footprinting System Kit (Promega). DNA probes were
dephosphorylated, labeled at both ends with (γ32P)-ATP
(Hartmann Analytic) by T4 polynucleotide kinase, and
digested with an restriction enzyme that released one of
the labeled ends. Probes were purified on an agarose gel
and DNA was recovered with the Qiaquick Gel Extraction
Kit (Qiagen). 5 ng of the labeled probe were incubated
with 5 µg nuclear extract in 50 µl of 25 mM Tris-HCl (pH
8.0), 50 mM KCl, 6.25 mM MgCl2, 1 mM EDTA, 20% glyc-
erol and 1 mM DTT for 20 min on ice and then, 50 µl of a
5 mM CaCl2/10 mM MgCl2 solution was added. After 1
min at room temperature, various amounts (0.15 – 1.5
units) of RQ1 RNase-free DNase I were added in order to
obtain an even DNase I ladder from top to the bottom of
the gel, mixed gently, and after 2 min of incubation the
reaction was terminated with 90 µl stop solution (200
mM NaCl, 30 mM EDTA, 1% SDS, 100 µg/ml yeast RNA).
DNA was extracted with phenol/chloroform/isoamylalco-
hol 1:1:1, precipitated with ethanol, and the pellet was
dissolved in loading solution (1:2 0.1 M NaOH:forma-
mide (v/v), 0.1% cylene cyanol, 0.1% bromphenol blue).
After heating the probes 2 min at 95°C and chilling on ice,
they were loaded onto a 6% polyacrylamide sequencing
gel containing 8 M urea and run in 1 × TBE buffer at 1500
Volt. Gels were dried on a filter paper and exposed to a
Kodak Phosphor screen. A sequencing reaction of the
respective DNA probe was carried out with the Sequenase
Version 2.0 DNA Sequencing Kit (USB Corp.) using
(α35S)-dATP (New England Nuclear) in the reaction mix-
ture and was run side by side with the footprint assay.
Images were analyzed with a STORM 830 facility (Molec-
ular dynamics).
Electrophoretic mobility shift assays (EMSAs)
Double-stranded oligonucleotide probes were 5'-endla-
beled with (γ32P)-ATP and T4 polynucleotide kinase.
EMSAs were carried out in a 10 µl reaction containing 3 µg
of nuclear extract, 250 ng poly(dI-dC), 2 µl of 5 × binding
buffer (50 mM HEPES, pH 7.9, 50 mM KCl, 25 mM
MgCl2, 2.5 mM EDTA, 40% glycerol, 5 mM DTT, 0.1%
NP40, 200 µg/ml BSA) and labeled oligo probe (80
fmoles, 20.000 cpm) for 15 min on ice. Competitive
EMSAs were performed under identical conditions by
adding the 50 or 100 fold amount of the same unlabeled
doublestranded oligo or an unspecific oligo as negative
control. For supershift experiments, 1.5 or 1 µl of anti-
human Sp1-, or Sp3-specific antibodies (Santa Cruz) or
unspecific rabbit IgG were added to the reaction mix and
incubated for 20 min on ice. Protein-DNA complexes
were resolved on a 4.5% nondenaturing polyacryamide
gel with Tris-EDTA buffer (45 mM Tris, 44.5 mM borate,
1 mM EDTA, pH 8.0) at 350 V at 4°C. Gels were dried on
filter paper, exposed 1 to 5 days to a Kodak Phosphor
screen and scanned with a STORM 830 facility.
Western blot analysis
Nuclear extracts or total lysates from MG63 and Saos-2
cells were applied to 10% SDS-PAGE and transferred onto
nitrocellulose membrane. Western analysis was per-
formed by incubating the membrane with rabbit anti-Sp1,
-Sp3, -TFIIB, or -GAPDH antibodies (Santa Cruz), fol-
lowed by HRP-conjugated secondary antibodies. Signals
were detected by enhanced chemiluminescence using an
ECL kit (Amersham Pharmacia). Densitometric quantifi-
cation was perfomed with the LumiAnalyst 3.0 program
(Roche).
ChIP assay
ChIP assays were performed with a ChIP kit (Upstate)
according to the manufacturer's recommendations. For
each chromatin immunoprecipitation assay, 2 – 3 × 107
cells (80 – 90% confluency) were crosslinked with 1% for-
maldehyde at room temperature for 20 min. Cells were
washed twice with ice-cold PBS, scraped from the culture
dish and resuspended in SDS lysis buffer (Upstate). Chro-
matin was fragmented by sonication (Labsonic U, B.
Braun) in 20 sec pulses on ice to an average size of 600 bp.
The lysates were diluted 1:10 with dilution buffer and pre-
cleared by adding 75 µl protein A agarose for 30 min at
4°C. 40 µl of the lysate were removed as control inputBMC Molecular Biology 2007, 8:20 http://www.biomedcentral.com/1471-2199/8/20
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DNA and microcentrifuged at full speed for 10 sec to pel-
let residual cell debris. IP was performed by adding 4 µg
anti-Sp1 antibody (Upstate), 4 µg anti-Sp3 antibody
(Upstate) or 5 µg unspecific rabbit IgG overnight at 4°C
under rotation, and an aliquot was incubated without
antibody. Immunocomplexes were precipitated by addi-
tion of protein A agarose for 1 hr at 4°C. Precipitates were
washed once with low salt buffer, once with high salt
buffer, once with LiCl buffer and twice with TE buffer
(Upstate). Protein/DNA complexes were eluted from the
antibodies with 1% SDS, 0.1 M NaHCO3, and DNA-pro-
tein interactions were reversed by addition of 5 M NaCl
and heating to 65°C for 4 hrs. Proteins were digested with
proteinase K for 1 hr at 45°C. Remaining DNA was puri-
fied by phenol/chloroform extraction and subsequent
ethanol precipitation. The DNA was finally resuspended
in 40 µl 1 × TE, pH 8.0, and 4 µl of the DNA was used for
each PCR reaction. Site-specific PCR was carried out using
primer pairs located at binding sites Sp1.1/Sp1.2 (193
bp), Sp1.3 (184 bp) and Sp1.4 (115 bp). PCR primers
were designed as 19–26 mers with ~55% GC content. PCR
was performed with a hot start, followed by 30 – 35 cycles
of 30 s at 95°C, 1 min annealing at 63°C, 65°C and 68°C
for each Sp1 site, respectively, and 30 s extension at 72°C.
Besides that, input DNA was used concentrated (4 µl) and
in 1:4 and 1:16 dilutions in PCR reactions. PCR products
were run on a 2% agarose gel and visualized by ethidium
bromide staining. Each ChIP experiment was carried out
at least three times with similar results.
Genomic DNA southern blot analysis
Genomic DNA was extracted from MG63 and Saos-2 cells
according to Sambrook et al. [65]. Briefly, genomic DNA
was isolated by cell lysis with proteinase K (Promega)
digestion and extraction with phenol/chloroform. After
precipitation, DNA was digested with the restriction
enzyme PstI to generate a 3989 bp podoplanin promoter
fragment ranging from bp -2799 to bp +1190 and then
with the isoschizomeric restriction enzymes HpaII and
MspI (NEB) with the binding site 5'-CCGG-3' to release
methylation-sensitive and -insensitive fragments. DNA
fragments were separated on a 1.5% agarose gel, trans-
ferred onto a nylon membrane and hybridized with five
radioactively labeled probes (P/B, F2/K, F5/Bs, Ex1, Int1).
After hybridization and subsequent washing, autoradio-
graphs were analyzed with a STORM 830 facility.
Sodium bisulfite genomic DNA sequencing
Bisulfite genomic sequencing was performed as described
previously [29]. Briefly, genomic DNA (5 µg) was dena-
tured in 0.3 M NaOH at 37°C for 15 min. Then, 3 M
sodium bisulfite (Sigma) and 10 mM hydroquinone
(Sigma) were added and samples were incubated at 50°C
for 16 h. The modified DNA was purified through the
Wizard Clean-Up system (Promega) and denatured by
addition of 0.3 M NaOH at 37°C for 15 min. DNA was
precipitated, resuspended in 1 mM Tris-HCl, pH 8 and
used for PCR reactions. Three regions were amplified with
primer pairs specific for bisulfite-reacted upper strands
(Table 1). PCR was performed with DNA isolated from
four independent bisulfite treatment experiments and
PCR products were cloned into pCR2.1-TOPO vector
(Invitrogen). Fifty to eighty clones from each reaction
were analyzed by sequencing.
5-AzaCdR and TSA treatment
Viability of MG63 and Saos-2 cells under the influence of
DNA methyltransferase inhibitor 5-azaCdR was tested up
to concentrations of 1, 10 and 50 µM, and for histone
deacetylase inhibitor TSA up to concentrations of 1, 2 and
3 µM over a period of 72 hrs. 5-azaCdR was added for 48
h at a final concentration of 1 µM, and TSA was added for
24 h alone, or for additional 24 h at the end of 5-azaCdR
treatment final concentrations of 0.3 and 0.6 µM. Cells
then were used for RNA isolation and subsequent quanti-
tative Northern blotting analysis as described above. Den-
sitometric quantification was perfomed with the
LumiAnalyst 3.0 program (Roche).
In vitro methylation of oligos and reporter plasmids
SssI methylase (NEB) was used for the methylation of
EMSA oligos and of PDPN promoter-luciferase constructs.
Oligos, pGL3-II and pGL3-I plasmid DNA were incubated
with methylase according to the manufacturers' recom-
mendations. Region-specific methylation was carried out
after excision with SacI/XhoI and SacI/ApaI to isolate the
promoter fragments -1885/+171, -1885/-189 from pGL3-
II and -857/+171 and -857/-189 from pGL3-I, as
described previously [31]. In each case, half of the DNA
was methylated in the absence of S-adenosyl-methionine
as mock methylation. The efficiency of methylation was
determined with the methylation-sensitive enzyme HpaII.
Methylated and mock-methylated fragments were reli-
gated into their descendant plasmids and equal amounts
were transfected into MG63 and Saos-2 cells.
Statistical analyses
Statistical relevant differences were assigned to a p-value
of at least ≤0.05 using Student's paired t-test.
List of abbreviations
PDPN, gene name for podoplanin; HEPES, 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid; DTT, dithiothre-
itol; EMSA, electrophoretic mobility shift assay; 5-
azaCdR, 5-aza-2'-deoxycytidine; TSA, trichostatin; S.D.,
standard deviation.
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